Assay of glutamine synthetase in cerebrospinal fluid as a specific marker in Alzheimer's disease

Abstract

There is, at present, no recognised diagnostic biochemical marker of Alzheimer's Disease (AD). Recently, Gunnerson and Haley, (1992), reported that the presence of glutamine synthetase (GS) in cerebrospinal fluid (CSF) samples showed a 97% correlation with patients diagnosed as having AD. GS was detected by photolabelling with [y32P]2-azido-ATP or [y32P]8azido- ATP and visualisation following sodium dodecyl sulphate polyacrylamide gel electrophoresis (SOS-PAGE) and autoradiography. This study set out to reproduce Gunnerson and Haley's methodology for labelling sheep GS in CSF using [y32P]8-azidoATP, to develop this assay or possibly another, using a fluorescent probe of ATP binding sites, into a robust procedure suitable for a routine diagnostic laboratory, and finally to assess whether the presence of GS in CSF is indeed a marker of AD.